Category

Research
This article was originally posted on AJMC Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition. Each March, Multiple Myeloma Awareness Month puts multiple myeloma (MM) in the spotlight. A rare cancer, MM is not easily diagnosed early on, but it is the second most common blood cancer...
Continue Reading
This article was originally published by Urbanhealth Today ABSTRACT BACKGROUND: The current standard of care for multiple myeloma requires several regimens of treatment, with patients experiencing high symptom burden and side effects, which negatively impact health-related quality of life (HRQoL). Thus, it is crucial to understand patient perceptions of multiple myeloma and how patients value...
Continue Reading
This article was originally published on News Medical Life Sciences Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells’ metabolism. These changes can be used as...
Continue Reading
Dear Colleagues On behalf of Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) please find below our article of the week and the current IMS COVID-19 vaccination guidelines. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With CancerVan Poznak, Unger, Darke, Moinpour, Bagramian, Schubert, Hansen, Floyd, Dakhil, Lew, Wade, Fisch, Henry,...
Continue Reading
This article was originally posted on Ubranhealth Today A study published in Cancers examined whether type of insurance is independently associated with overall survival (OS) among patients with multiple myeloma (MM). The investigators used the National Cancer Database to identify 117,926 patients with MM who were diagnosed between 2005 and 2014. The median patient age was 67 years. At...
Continue Reading
This article was originally published on AJMC DDespite advances in treatment for multiple myeloma (MM), patients’ socioeconomic status (SES) is a significant factor in predicting survival rates, according to a wide-ranging review of studies on the disease. Researchers from Greece performed a meta-analysis of 16 studies in the United States and worldwide to examine the correlation between...
Continue Reading
This article was originally posted on News hub A haematologist is calling for increased funding towards blood cancer treatments in New Zealand, arguing there is a lack of awareness regarding the diseases that kill an estimated 800 Kiwis each year. Ken Romeril, a haematologist with a specialist interest in myeloma, is the chief executive of...
Continue Reading
This article was originally published on Urbanhealth Today Across the globe, socioeconomic status (SES) was shown to be a prognosis factor for overall survival (OS) among patients with multiple myeloma (MM), according to a new study. Previous studies have established an association between low SES and increased rates of cancer mortality. In this study, researchers from...
Continue Reading
This article was originally published on Urbanhealth Today ABSTRACT Multiple myeloma (MM) is a malignancy of plasma cells characterized by the clonal proliferation of plasma cells that produce monoclonal immunoglobulins. While typically considered to be incurable, advances in treatment options have led to remarkable improvements in survival for these patients. Accumulating evidence suggests an increased...
Continue Reading
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple myeloma (MM), authors reported in a meta-analysis published in Blood Advances. This association was seen in transplant-eligible and transplant-ineligible patients and those with newly diagnosed and relapsed or refractory disease. Lead study...
Continue Reading
1 2 3 4 7

Floor 7, 90 The Terrace
Wellington Central
New Zealand